Identifiant pérenne de la notice : 212499386
Notice de type
Notice de regroupement
Note publique d'information : Drug Discovery and Evaluation has become a more and more difficult, expensive and
time-consuming process. The effect of a new compound has to be detected by in vitro
and in vivo methods of pharmacology. The activity spectrum and the potency compared
to existing drugs have to be determined. As these processes can be divided up stepwise
we have designed a book series "Drug Discovery and Evaluation" in the form of a recommendation
document. The methods to detect drug targets are described in the first volume of
this series "Pharmacological Assays" comprising classical methods as well as new technologies.
Before going to man, the most suitable compound has to be selected by pharmacokinetic
studies and experiments in toxicology. These preclinical methods are described in
the second volume "Safety and Pharmacokinetic Assays". Only then are first studies
in human beings allowed. Special rules are established for Phase I studies. Clinical
pharmacokinetics are performed in parallel with human studies on tolerability and
therapeutic effects. Special studies according to various populations and different
therapeutic indications are necessary. These items are covered in the third volume:
"Methods in Clinical Pharmacology".
paprika.idref.fr
data.idref.fr
Documentation
